Table 2.
Incidence of recurrent peptic ulcer during 24 weeks of treatment in subgroups stratified by baseline characteristics
| Characteristic | Recurrence rate, % (n/N) | ||
| Lansoprazole 15 mg | Vonoprazan 10 mg | Vonoprazan 20 mg | |
| Helicobacter pylori status | |||
| Negative | 3.3 (4/123) | 0.9 (1/114) | 2.6 (3/116) |
| Positive | 2.3 (2/86) | 0 (0/83) | 0 (0/79) |
| CYP2C19 genotype | |||
| Extensive metaboliser | 2.7 (5/184) | 0.6 (1/162) | 1.3 (2/155) |
| Poor metaboliser | 3.6 (1/28) | 0 (0/35) | 2.4 (1/41) |
| Age | |||
| <65 years | 1.4 (1/69) | 1.9 (1/53) | 0 (0/50) |
| ≥65 to <75 years | 2.2 (2/90) | 0 (0/91) | 2.0 (2/99) |
| ≥75 years | 5.6 (3/54) | 0 (0/53) | 2.1 (1/47) |
| Smoking status | |||
| Current or ex-smoker | 1.8 (3/165) | 0.6 (1/155) | 1.9 (3/155) |
| Never smoker | 6.3 (3/48) | 0 (0/42) | 0 (0/41) |
| Alcohol consumption status | |||
| Drinker | 1.7 (2/119) | 0.8 (1/126) | 0.9 (1/117) |
| Never drink | 4.3 (4/94) | 0 (0/71) | 2.5 (2/79) |
| Oral antithrombotic drug* | |||
| Yes | 2.2 (2/91) | 0 (0/83) | 2.5 (2/79) |
| No | 3.3 (4/122) | 0.9 (1/114) | 0.9 (1/117) |
*Additional analysis.
CYP, cytochrome P450.